FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	OMB APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average burde	en									
l	hours ner resnonse:	0.5									

1. Name and Address of Reporting Person* <u>KING STEVEN W</u>					2. Issuer Name and Ticker or Trading Symbol  5. Relationship of Reporting Person(s) to Issuer  DEDECTINE DIADMACELITICALS INC. [ (Check all applicable)									ier				
					PEREGRINE PHARMACEUTICALS INC [ PPHM ]							<u>~ [ ]</u> `	X	Director	,		10% Ov	vner
(Last)	(F	irst)	(Middle)										X	Officer (give title below)			Other (s below)	specify
C/O PEREGRINE PHARMACEUTICALS, INC					3. Date of Earliest Transaction (Month/Day/Year) 01/11/2008								President & CEO					
14282 Fl	RANKLIN .	AVENUE																
(Street)				—   <sup>4.</sup>	If Ame	endment, I	Date o	f Original F	iled (	Month/Da	y/Year)		indı Line)	vidual or Jo	oint/Group	Filing	(Check App	licable
TUSTIN	, C.	A	92780										X	Form fil	ed by One	Repo	rting Persor	1
												Form filed by More than One Reporting Person				ting		
(City)	(S	tate)	(Zip)															
		Та	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, I	Disp	osed o	f, or Be	neficia	ally	Owned				
, , , Da						2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Dispose Code (Instr. 5)		rities Acquired (A) ed Of (D) (Instr. 3, 4		5. Amour Securitie Beneficia Owned F Reported		lly ollowing	Form:	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	Amount (A) or (D)		e	Transaction(s) (Instr. 3 and 4)				(50. 4)
Common Stock, \$0.001 par value													91,555		555		D	
			Table II - De (e.					uired, Di , option						wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. ) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
												Amoun	ıt		(Instr. 4)	ion(s)		
				Code	\v	(A)	(D)	Date Exercisable		xpiration ate	Title	Numbe of Shar						
Incentive Stock Option (right to	\$0.39	01/11/2008		A		250,000		(1)	0:	1/11/2018	Common Stock	250,0	00	\$0	1,360,8	333	D	

## Explanation of Responses:

1. Option will vest over 24 equal monthly installments.

## Remarks:

/s/ Steven W. King

\*\* Signature of Reporting Person

01/11/2008

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).